Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 740 for:    ABP 501

A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05414201
Recruitment Status : Recruiting
First Posted : June 10, 2022
Last Update Posted : July 26, 2022
Sponsor:
Information provided by (Responsible Party):
AbbVie

Brief Summary:

Non-infectious intermediate-, posterior- and pan-uveitis (NIIPPU) are sight threatening diseases with a high patient burden and negative impact on quality of life. Corticosteroids remain the mainstay of first-line treatment for NIIPPU in China despite serious side effects associated with long-term and high-dose corticosteroid use. Adalimumab is used to treat NIIPPU in adults who have had inadequate response to corticosteroids, or who need corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. The purpose of this study is to assess adverse events and effectiveness of adalimumab in Chinese participants requiring high dose corticosteroids with NIIPPU.

Adalimumab is a conditionally approved drug in China used to treat participants with NIIPPU. All participants will receive the same treatment. Approximately 87 adult participants will be enrolled at approximately 15 sites in China.

Participants will receive one subcutaneous loading dose of adalimumab at baseline followed a week later by a lower dose of adalimumab every other week for up to 30 weeks.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.


Condition or disease Intervention/treatment Phase
Non-infectious Intermediate Posterior- or Pan-uveitis Drug: Adalimumab Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 87 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-label, Single-arm Study to Demonstrate the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Chinese Subjects Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate-, Posterior-, or Pan-uveitis
Actual Study Start Date : July 7, 2022
Estimated Primary Completion Date : October 10, 2023
Estimated Study Completion Date : October 10, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Steroids
Drug Information available for: Adalimumab

Arm Intervention/treatment
Experimental: Adalimumab
Participants will receive a loading dose of Adalimumab 80mg SC at Baseline followed a week later by a dose of Adalimumab 40mg SC every other week.
Drug: Adalimumab
Subcutaneous Injection
Other Name: Humira




Primary Outcome Measures :
  1. Percentage of participants that achieve quiescence in both eyes [ Time Frame: Week 30 ]
    Quiescence is defined as no active inflammatory chorioretinal and/or inflammatory retinal vascular lesions, anterior chamber (AC) cell grade ≤ 0.5+ and vitreous haze (VH) grade ≤ 0.5+


Secondary Outcome Measures :
  1. Percentage of participants that achieve no active lesions in both eyes [ Time Frame: Week 30 ]
    Percentage of participants that achieve no active lesions in both eyes.

  2. Percentage of participants that achieve Anterior Chamber (AC) cell grade ≤ 0.5+ in both eyes [ Time Frame: Week 30 ]

    Slit lamp examinations will be conducted at each visit to assess AC cell count. The number of AC cells observed within a 1 mm × 1 mm slit beam will be used to determine the grade according to the Standardization of Uveitis Nomenclature (SUN) criteria:

    Grade 0 = < 1 cell Grade 0.5+ = 1 - 5 cells Grade 1+ = 6 - 15 cells Grade 2+ = 16 - 25 cells Grade 3+ = 26 - 50 cells Grade 4+ = > 50 cells.


  3. Percentage of participants that achieve Vitreous Haze (VH) grade ≤ 0.5+ in both eyes [ Time Frame: Week 30 ]

    Vitreous haze was measured using dilated indirect ophthalmoscopy (DIO) and assessed by the Investigator according to National Eye Institute (NEI) and SUN criteria:

    Grade 0: No evident vitreous haze; Grade 0.5+: Slight blurring of the optic disc margin because of the haze; normal striations and reflex of the nerve fiber layer cannot be visualized; Grade 1+: Permits a better definition of both the optic nerve head and the retinal vessels (compared to higher grades); Grade 2+: Permits better visualization of the retinal vessels (compared to higher grades); Grade 3+: Permits the observer to see the optic nerve head, but the borders are quite blurry; Grade 4+: Optic nerve head is obscured.


  4. Percentage of participants that achieve no worsening of Best Corrected Visual Acuity (BCVA) by ≥ 15 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) in both eyes [ Time Frame: Week 30 ]
    Using the appropriate corrective lenses based on that visit's refraction, participant's BCVA is measured using an ETDRS chart.

  5. Percentage of participants that achieve a ≥ 50% reduction in immunosuppression load [ Time Frame: Week 30 ]
    Achievement of a ≥ 50% reduction in immunosuppression load

  6. Percentage of participants that achieve a systemic corticosteriods dose ≤ 7.5 mg [ Time Frame: Week 30 ]
    Achievement of a systemic corticosteriods (CS) dose of ≤ 7.5 mg



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female of Chinese descent, with full Chinese parentage.
  • Diagnosed with active non-infectious intermediate uveitis, posterior uveitis, or panuveitis defined by the presence of at least 1 of the following in at least one eye:

    • Active, inflammatory chorioretinal, and/or inflammatory retinal vascular lesion
    • ≥ 2+ anterior chamber cells (Standardization of Uveitis Nomenclature [SUN] criteria); or
    • ≥ 2+ vitreous haze (National Eye Institute [NEI]/SUN criteria).
  • Receiving oral prednisone from ≥ 10mg/day to ≤ 60mg/day (or oral corticosteroids equivalent) for at least two weeks before Screening and remaining on the same dose from Screening to Baseline.

Exclusion Criteria:

  • Participants with the following ocular events:

    • Isolated anterior uveitis;
    • Confirmed or suspected infectious uveitis;
    • Ocular masquerade syndromes, such as ocular lymphoma;
    • Presumed ocular histoplasmosis syndrome;
    • Serpiginous choroidopathy;
    • Scleritis;
    • Corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the trial;
    • Macular edema as the only sign of uveitis;
    • Severe VH that precludes visualization of the fundus at the Baseline visit;
    • Intraocular pressure of ≥ 25 mmHg and on ≥ 2 glaucoma medications or evidence of glaucomatous optic nerve injury;
    • Best Corrected Visual Acuity less than 20 letters (ETDRS) in either eye at the Baseline visit;
    • Proliferative or severe non-proliferative diabetic retinopathy or clinically significant macular edema due to diabetic retinopathy;
    • Neovascular/wet age-related macular degeneration;
    • Abnormality of vitreo-retinal interface (i.e., vitreomacular traction, epiretinal membranes, etc.) with the potential for macular structural damage independent of the inflammatory process.
    • Ocular surgery within 90 days prior to the Baseline visit with the exception of refractive laser surgery or retinal laser photocoagulation or YAG (neodymium-doped yttrium aluminium garnet) posterior capsulotomy. These three exceptions are exclusionary within 30 days prior to Baseline.
  • Previous exposure to anti-TNF therapy or any biologic therapy with a potential therapeutic impact on non-infectious uveitis.
  • Has received glucocorticosteroid implant, Ozurdex® (dexamethasone implant), intravitreal adalimumab, Methotrexate (MTX) or anti-VEGF therapy at any time prior to the Baseline visit.
  • Infection(s) requiring treatment with IV anti-infectives within 30 days prior to the Baseline visit or oral anti-infectives within 14 days prior to the Baseline visit.
  • Participant on cyclophosphamide within 30 days prior to the Baseline visit.
  • Participant has received cyclophosphamide within 30 days prior to the Baseline visit.
  • Participant treated with any investigational drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another clinical study.
  • Participant received any live vaccine within 4 weeks prior to the first dose of study drug, or expected need of live vaccination during study participation including at least 4 weeks after the last dose of study drug.
  • Participant treated with oral traditional Chinese medicine within 14 day prior to the first dose of study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05414201


Contacts
Layout table for location contacts
Contact: ABBVIE CALL CENTER 844-663-3742 abbvieclinicaltrials@abbvie.com

Locations
Layout table for location information
China, Beijing
Peking University First Hospital /ID# 243055 Not yet recruiting
Beijing, Beijing, China, 100034
Peking Union Medical College Hospital /ID# 243057 Not yet recruiting
Beijing, Beijing, China, 100730
China, Shanghai
Shanghai General hospital /ID# 247252 Not yet recruiting
Shanghai, Shanghai, China, 200080
China, Zhejiang
The second Affiliated hospital of Zhejiang University school of Medicine /ID# 247251 Not yet recruiting
Hangzhou, Zhejiang, China, 310009
China
Beijing Tongren Hospital, CMU /ID# 243054 Not yet recruiting
Beijing, China, 100730
The first affiliated hospital of chongqing medical university /ID# 242971 Not yet recruiting
Chongqing, China, 400016
Tianjin Medical University Eye Hospital /ID# 243056 Recruiting
Tianjin, China, 300384
Eye hospital,WMU Zhejiang Eye Hospital /ID# 247253 Not yet recruiting
Wenzhou, China, 325612
Xi'an people's hospital/Xi'an fourth hospital /ID# 243371 Not yet recruiting
XI An, China, 710000
Sponsors and Collaborators
AbbVie
Investigators
Layout table for investigator information
Study Director: ABBVIE INC. AbbVie
Additional Information:
Layout table for additonal information
Responsible Party: AbbVie
ClinicalTrials.gov Identifier: NCT05414201    
Other Study ID Numbers: M20-387
First Posted: June 10, 2022    Key Record Dates
Last Update Posted: July 26, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access Criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
URL: https://vivli.org/ourmember/abbvie/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by AbbVie:
Humira
Adalimumab
Additional relevant MeSH terms:
Layout table for MeSH terms
Uveitis
Panuveitis
Uveal Diseases
Eye Diseases
Adalimumab
Anti-Inflammatory Agents
Antirheumatic Agents